-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, License-in/out has gradually emerged in the Chinese medical circle
.
The Licensein model allows domestic companies to quickly obtain advanced research results in the industry, quickly enrich their own R&D pipelines, and make up for their own team's shortcomings
In the current increasingly fierce market competition, more and more companies are seeking to obtain new business breakthroughs through the Licensein/out model, and one of the key factors for the results of the Licensein/out project is the choice of its varieties
.
.
There are obvious differences among people in different regions in terms of race, genetics, physiology and pathology, living and eating habits, living environment, social economy, medical measures, and drug compliance
.
Therefore, there are differences in pathogenesis, morbidity, treatment methods and drug efficacy
According to statistics from the World Health Organization, the top three causes of death in China are stroke, heart disease and cancer
.
The top three fatalities in the United States are heart disease, Alzheimer's disease and other dementias, and cancer
Provides market space for excess profits for Licensein/out projects
Similarly, the incidence of breast cancer, pancreatic cancer, prostate cancer, non-Hodgkin's lymphoma, bladder cancer and other cancers in the United States is significantly higher than in China
.
When domestic companies choose products to go overseas, they can also give priority to the research results of these cancers
Figure 1 Differences in tumor epidemiology between China and the United States in 2020
On the basis of the difference in tumor incidence, the difference in the proportion of mutation sites also has reference value
.
As far as the highly anticipated non-small cell lung cancer is concerned, the mutation target differences between China and the United States are equally significant
Figure 2 Comparison of mutation sites of lung adenocarcinoma in China and the United States
In lung squamous cell carcinoma, the proportion of FBXW7, RB1, KEAP1, CDKN2A and other mutations in Chinese patients is significantly higher than that in the United States; while the proportion of TP53, PIK3CA, NSD1, and WWC3 mutations in the United States is significantly higher than that in China
Figure 3 Comparison of mutation sites of lung squamous cell carcinoma in China and the United States
The Licensein/out model provides a fast lane for the innovation and development of China's biomedicine, and it is also conducive to making the best use of the global innovation achievements
